These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1391037)

  • 41. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study.
    Reali UM; Martini L; Borgognoni L; Semino C; Pietra G; Chiarugi C; Guastella M; Melioli G
    Melanoma Res; 1998 Feb; 8(1):77-82. PubMed ID: 9508381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
    Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
    J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC; Belldegrun A; Figlin RA
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract]   [Full Text] [Related]  

  • 45. [Role of cell therapy in the management of cancer].
    Fridman WH; Mathiot C; Tartour E; Dorval T; Thiounn N; Pouillart P; Debre B
    Bull Cancer; 1995 Mar; 82(3):235-6. PubMed ID: 7655161
    [No Abstract]   [Full Text] [Related]  

  • 46. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma.
    Ratto GB; Zino P; Mirabelli S; Minuti P; Aquilina R; Fantino G; Spessa E; Ponte M; Bruzzi P; Melioli G
    Cancer; 1996 Jul; 78(2):244-51. PubMed ID: 8673999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene therapy of cancer.
    Rosenberg SA
    Important Adv Oncol; 1992; ():17-38. PubMed ID: 1582673
    [No Abstract]   [Full Text] [Related]  

  • 48. Tumor infiltrating lymphocytes.
    Davidson AT
    J Natl Med Assoc; 1990 Sep; 82(9):612-3, 616. PubMed ID: 2213908
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
    Oldham RK
    Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
    [No Abstract]   [Full Text] [Related]  

  • 50. Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above.
    Karp DD; Atkins MB
    Cancer; 1996 Jul; 78(2):195-8. PubMed ID: 8673991
    [No Abstract]   [Full Text] [Related]  

  • 51. Adoptive T-cell transfer in melanoma.
    Itzhaki O; Levy D; Zikich D; Treves AJ; Markel G; Schachter J; Besser MJ
    Immunotherapy; 2013 Jan; 5(1):79-90. PubMed ID: 23256800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study.
    Cascinelli N; Foà R; Parmiani G; Arienti F; Belli F; Bernengo MG; Clemente C; Colombo MP; Guarini A; Illeni MT
    Hum Gene Ther; 1994 Aug; 5(8):1059-64. PubMed ID: 7948140
    [No Abstract]   [Full Text] [Related]  

  • 53. Musings on the struggle--Part V: Beginning the N2/TIL protocol.
    Anderson WF
    Hum Gene Ther; 1994 Apr; 5(4):427-8. PubMed ID: 8049300
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical application of gene transfer in cancerology].
    Favrot M; Philip T; Merrouche Y
    Bull Cancer; 1995 Mar; 82(3):234-5. PubMed ID: 7655160
    [No Abstract]   [Full Text] [Related]  

  • 55. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
    Rosenberg SA
    J Clin Oncol; 1992 Feb; 10(2):180-99. PubMed ID: 1732421
    [No Abstract]   [Full Text] [Related]  

  • 56. Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes.
    Parmiani G; Fossati G; Radrizzani M; Gambacorti-Passerini C; Marolda R; Cascinelli N
    Adv Exp Med Biol; 1988; 233():453-8. PubMed ID: 3265580
    [No Abstract]   [Full Text] [Related]  

  • 57. Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy.
    Whiteside TL; Jost LM; Herberman RB
    Crit Rev Oncol Hematol; 1992 Jan; 12(1):25-47. PubMed ID: 1540337
    [No Abstract]   [Full Text] [Related]  

  • 58. Disseminated malignant melanoma. New therapeutic approaches.
    Stadler R; Garbe C
    Int J Dermatol; 1991 Apr; 30(4):239-42. PubMed ID: 1711019
    [No Abstract]   [Full Text] [Related]  

  • 59. Advances in the development of tumor-infiltrating lymphocyte therapy for advanced melanoma.
    Julve M; Furness AJ
    Expert Opin Biol Ther; 2023 Apr; 23(4):319-323. PubMed ID: 36932721
    [No Abstract]   [Full Text] [Related]  

  • 60. Lack of effect of tumour infiltrating lymphocytes in patients with metastatic melanoma who failed to respond to interleukin 2.
    Dorval T; Mathiot C; Brandely M; Escande MC; Fridman WH; Pouillart P
    Eur J Cancer; 1992; 28(2-3):615-6. PubMed ID: 1591084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.